It happened. Yesterday, April 1, 2026, the FDA approved Foundayo (orforglipron) — Eli Lilly's oral GLP-1 pill for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. This is the biggest GLP-1 approval since Wegovy in 2021, and it is not even close.
What makes this approval historic is not just the drug itself — it is the speed. The FDA cleared Foundayo in just 50 days under the National Priority Voucher program, making it the fastest new molecular entity approval since 2002. Eli Lilly earned the priority voucher through its rare disease work and redeemed it here, shaving months off the standard review timeline. The original PDUFA date was April 10. The FDA beat it by nine days.
Foundayo is now the second oral GLP-1 approved for obesity, joining oral Wegovy (oral semaglutide) which launched in December 2025. But calling them competitors undersells how different they are in practice.
Why Foundayo Changes Everything
Here is the single most important thing about Foundayo: you can take it at any time of day, with food, with coffee, with your other medications. No empty stomach. No 30-minute fasting window. No carefully timed sip of 4 ounces of plain water. Just swallow a pill like any other medication you take.
This matters more than the clinical trial numbers suggest. The number one complaint we hear from oral Wegovy users — and we have documented this extensively in our [3-month oral Wegovy review](/blog/oral-wegovy-3-month-review) — is the fasting requirement. Patients describe it as disruptive, stressful, and hard to maintain long-term. Pharmacy refill data backs this up: oral Wegovy has a 78% refill rate at 90 days compared to 85% for the injectable. People are dropping off because the daily dosing ritual is too annoying.
Foundayo eliminates that problem entirely. Orforglipron is a small molecule, not a peptide like semaglutide. It does not need an absorption enhancer or an empty stomach to survive your digestive tract. It just works. Take it with breakfast, take it at lunch, take it before bed with a snack. The drug does not care, and neither do you.
Foundayo vs. Oral Wegovy: Head-to-Head
Here is how the two oral GLP-1 options compare right now:
Oral Wegovy (semaglutide 50mg): Approved December 2025. Peptide-based drug requiring SNAC absorption enhancer. Average weight loss of 13.6% at 68 weeks (50mg dose, real-world adjusted). Must be taken every morning on an empty stomach with no more than 4 ounces of plain water, then wait 30 minutes before eating or drinking. List price around $1,200/month, with most patients paying $149-249/month through insurance or savings programs.
Foundayo (orforglipron 60mg): Approved April 1, 2026. Small molecule — no absorption enhancer needed. Average weight loss of 11.2% at 72 weeks (60mg dose, primary endpoint). Take once daily at any time, with or without food, no restrictions. List price $799/month, with most patients expected to pay $149-299/month. Eli Lilly is launching a savings card that brings the cost to $25/month for commercially insured patients.
The weight loss difference is real — oral Wegovy has a 2-3 percentage point edge in clinical trials. But here is the thing about clinical trials: everyone takes the drug perfectly. In the real world, the medication you actually take every day beats the one you skip because you forgot to fast or could not deal with the morning routine. We expect real-world weight loss numbers to be much closer between the two.
Novo Nordisk Is Throwing Everything at the Wall
If you want to understand how threatened Novo Nordisk feels, look at what they did in the 48 hours surrounding this approval.
On March 31 — literally the day before Foundayo's approval — Novo Nordisk launched a $249/month direct-to-consumer Wegovy subscription program. Twelve-month commitment, telehealth included, no insurance required. This was not a coincidence. They wanted to lock in as many patients as possible before the Foundayo news dropped.
They are also rolling out Wegovy HD (7.2mg injectable) this month, which showed 20.7% total body weight loss in trials. That is a genuinely impressive number and significantly higher than either oral option. The message to patients: if you want maximum weight loss and you do not mind the needle, Wegovy HD is the most effective GLP-1 available.
It is a smart two-pronged defense — compete on price with the subscription and on efficacy with Wegovy HD. But it also tells you that Novo sees the oral GLP-1 market as the real battleground, and they know Foundayo's convenience advantage is a serious threat.
When Can You Get Foundayo?
Eli Lilly is moving fast on distribution:
April 6: LillyDirect (Lilly's direct-to-patient platform) begins shipping Foundayo. If you already have a Zepbound or Mounjaro prescription through LillyDirect, your provider can switch you to Foundayo immediately.
Mid-April: Major retail pharmacies (CVS, Walgreens, Walmart) are expected to begin dispensing. Lilly says they have pre-positioned inventory to avoid the shortage problems that plagued Mounjaro and Zepbound launches.
July 1: Medicare coverage begins under the Bridge program at $50/month — the same terms as Wegovy and Zepbound.
The $25 savings card: Eli Lilly is launching a commercial insurance savings card that brings patient out-of-pocket costs to $25/month for eligible commercially insured patients. This is the cheapest brand-name GLP-1 option on the market by a wide margin.
Should You Switch?
This depends entirely on your current situation:
If you are happy on an injectable GLP-1 (Wegovy, Zepbound, Ozempic, Mounjaro) — there is no rush to switch. Injectables still produce higher average weight loss, and once-weekly dosing is simpler than daily for many people. Foundayo is a daily pill. If your injectable is working and you do not mind the needle, stay the course.
If you are on oral Wegovy and hate the fasting requirement — Foundayo is what you have been waiting for. This is the clearest switching case. Same drug class, comparable efficacy, zero dosing restrictions. Talk to your prescriber now.
If you have been avoiding GLP-1 therapy because of needles AND the oral Wegovy routine seemed too complicated — Foundayo removes both barriers. A normal pill, taken whenever you want. This is as simple as GLP-1 therapy gets.
If cost is your biggest concern — the $25 savings card makes Foundayo the cheapest brand-name option available. Even without insurance, the $799 list price is lower than Wegovy ($1,200) or Zepbound ($1,060). And if you are Medicare-eligible, the $50/month Bridge program starts in July.
The Bottom Line
April 1, 2026 is a turning point for weight loss medication. Foundayo is not the most powerful GLP-1 on the market — that title belongs to Zepbound and the new Wegovy HD injectable. But it is the most convenient, the most accessible, and arguably the most important for expanding who can realistically use GLP-1 therapy long-term. A pill you take with breakfast and never think about again is a fundamentally different product than an injection you dread or an oral medication that demands a strict morning ritual.
Competition between Lilly and Novo Nordisk is driving prices down, expanding access, and giving patients real choices for the first time. This is what the GLP-1 market should have looked like from the beginning.
For the full deep dive on orforglipron's clinical data, dosing schedules, and side effect profile, read our [orforglipron guide](/guides/orforglipron). To compare all current GLP-1 options side by side, check our [Ozempic vs. Wegovy comparison](/compare/ozempic-vs-wegovy). And if you are ready to start and want to find the best provider, our [best GLP-1 providers ranking](/best) is updated monthly.
We will be covering the Foundayo launch closely over the coming weeks. Stay tuned.